ORCID as entered in ROS

Select Publications
2022, 'Frontline workers: Mediators of mucosal immunity in community acquired pneumonia and COVID-19', Frontiers in Immunology, 13, http://dx.doi.org/10.3389/fimmu.2022.983550
,2022, 'Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19 A Randomized Controlled Trial', Annals of Internal Medicine, 175, pp. 1266 - 1274, http://dx.doi.org/10.7326/M22-1503
,2022, 'Adaption of an ongoing clinical trial to quickly respond to gaps in changing international recommendations: the experience of D2EFT', HIV Research & Clinical Practice, 23, pp. 37 - 46, http://dx.doi.org/10.1080/25787489.2022.2103572
,2022, 'Standardized testing and written communication improve patient understanding of beta-lactam allergy testing outcomes: A multicenter, prospective study', Journal of Allergy and Clinical Immunology Global, 1, pp. 99 - 105, http://dx.doi.org/10.1016/j.jacig.2022.05.003
,2022, 'Targeted Nanocarrier Delivery of RNA Therapeutics to Control HIV Infection', Pharmaceutics, 14, http://dx.doi.org/10.3390/pharmaceutics14071352
,2022, 'PB2087: EFFICACY OF A 3RD COVID VACCINE, INCLUDING DURING A BTKI PAUSE, IN INDIVIDUALS WITH WALDENSTRÖM MACROGLOBULINEMIA AND FOLLICULAR LYMPHOMA', HemaSphere, 6, pp. 1958 - 1959, http://dx.doi.org/10.1097/01.hs9.0000851180.32970.18
,2022, 'Navigating the complexity of chronic HIV-1 associated immune dysregulation', Current Opinion in Immunology, 76, http://dx.doi.org/10.1016/j.coi.2022.102186
,2022, 'Platform for isolation and characterization of SARS-CoV-2 variants enables rapid characterization of Omicron in Australia', Nature Microbiology, 7, pp. 896 - 908, http://dx.doi.org/10.1038/s41564-022-01135-7
,2022, 'Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial', Lancet Infectious Diseases, 22, pp. 622 - 635, http://dx.doi.org/10.1016/S1473-3099(21)00751-9
,2022, 'Pacific Eclipse: Before the corona dawn', Vaccine, 40, pp. 2474 - 2475, http://dx.doi.org/10.1016/j.vaccine.2021.02.021
,2022, 'Myocardial fibrosis occurs in non-hospitalised patients with chronic symptoms after COVID-19', Ijc Heart and Vasculature, 39, http://dx.doi.org/10.1016/j.ijcha.2022.100964
,2022, 'The HIV-1 proviral landscape reveals that Nef contributes to HIV-1 persistence in effector memory CD4+ T cells', Journal of Clinical Investigation, 132, http://dx.doi.org/10.1172/JCI154422
,2022, 'Nanoparticle Delivery Platforms for RNAi Therapeutics Targeting COVID-19 Disease in the Respiratory Tract', International Journal of Molecular Sciences, 23, http://dx.doi.org/10.3390/ijms23052408
,2022, 'Plasma-Derived HIV-1 Virions Contain Considerable Levels of Defective Genomes', Journal of Virology, 96, http://dx.doi.org/10.1128/jvi.02011-21
,2022, 'Nanoscale probing and imaging of HIV-1 RNA in cells with a chimeric LNA-DNA sensor', Nanoscale, 14, pp. 3049 - 3061, http://dx.doi.org/10.1039/d1nr08418f
,2022, 'Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ T cell responses', Cell Reports, 38, pp. 110345, http://dx.doi.org/10.1016/j.celrep.2022.110345
,2022, 'Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection', Nature Immunology, 23, pp. 210 - 216, http://dx.doi.org/10.1038/s41590-021-01113-x
,2022, 'Early expansion of CD38+ICOS+ GC Tfh in draining lymph nodes during influenza vaccination immune response', Iscience, 25, pp. 103656, http://dx.doi.org/10.1016/j.isci.2021.103656
,2022, 'Myocardial Fibrosis Occurs in Non-Hospitalised Patients With Chronic Symptoms After COVID-19', Heart, Lung and Circulation, 31, pp. S169 - S170, http://dx.doi.org/10.1016/j.hlc.2022.06.267
,2022, 'PP 1.13 – 00078 CTL epitopes from structurally important hiv proteins are identified in rebound HIV', Journal of Virus Eradication, 8, pp. 100118 - 100118, http://dx.doi.org/10.1016/j.jve.2022.100118
,2021, 'Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability', Immunity, 54, pp. 2908 - 2921.e6, http://dx.doi.org/10.1016/j.immuni.2021.10.019
,2021, 'A single dose, BCG-adjuvanted COVID-19 vaccine provides sterilising immunity against SARS-CoV-2 infection', Npj Vaccines, 6, http://dx.doi.org/10.1038/s41541-021-00406-4
,2021, 'Characteristics of Agreements to have Condomless Anal Intercourse in the Presence of an Undetectable Viral Load Among HIV Serodiscordant Male Couples in Australia, Brazil and Thailand', AIDS and Behavior, 25, pp. 3944 - 3954, http://dx.doi.org/10.1007/s10461-021-03324-7
,2021, 'Evolution of HIV-1 Surveillance Drug Resistance Mutations over 10 Years in New South Wales, Australia', AIDS Research and Human Retroviruses, 37, pp. 897 - 902, http://dx.doi.org/10.1089/aid.2016.0301
,2021, 'Human MAIT cells respond to and suppress HIV-1', Elife, 10, http://dx.doi.org/10.7554/eLife.50324
,2021, 'Efficacy of Vaccine BNT162b2 (Pfizer-BioNTech) in Individuals with Waldenstrom's Macroglobulinemia and Follicular Lymphoma in Australia', BLOOD, 138, http://dx.doi.org/10.1182/blood-2021-149348
,2021, 'Inflammatory biomarkers and soft tissue changes among patients commencing second-line antiretroviral therapy after first-line virological failure', AIDS, 35, pp. 2289 - 2298, http://dx.doi.org/10.1097/QAD.0000000000003014
,2021, 'Intrinsic Defects in B Cell Development and Differentiation, T Cell Exhaustion and Altered Unconventional T Cell Generation Characterize Human Adenosine Deaminase Type 2 Deficiency', Journal of Clinical Immunology, 41, pp. 1915 - 1935, http://dx.doi.org/10.1007/s10875-021-01141-0
,2021, 'Limited recovery from post-acute sequelae of sars-cov-2 at 8 months in a prospective cohort', Erj Open Research, 7, http://dx.doi.org/10.1183/23120541.00384-2021
,2021, 'Increased targeted HIV testing and reduced undiagnosed HIV infections among gay and bisexual men', HIV Medicine, 22, pp. 605 - 616, http://dx.doi.org/10.1111/hiv.13102
,2021, 'Protective efficacy of the anti-HIV broadly neutralizing antibody PGT121 in the context of semen exposure', Ebiomedicine, 70, pp. 103518, http://dx.doi.org/10.1016/j.ebiom.2021.103518
,2021, 'SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants', PLoS Medicine, 18, http://dx.doi.org/10.1371/journal.pmed.1003656
,2021, 'Preservation of Gastrointestinal Mucosal Barrier Function and Microbiome in Patients With Controlled HIV Infection', Frontiers in Immunology, 12, pp. 688886, http://dx.doi.org/10.3389/fimmu.2021.688886
,2021, 'The role of zeb2 in human cd8 t lymphocytes: Clinical and cellular immune profiling in mowat–wilson syndrome', International Journal of Molecular Sciences, 22, pp. 5324, http://dx.doi.org/10.3390/ijms22105324
,2021, 'Factors Associated with and Characteristic of HIV/ Tuberculosis Co-Infection: A Retrospective Analysis of SECOND-LINE Clinical Trial Participants', Journal of Acquired Immune Deficiency Syndromes, 87, pp. 720 - 729, http://dx.doi.org/10.1097/QAI.0000000000002619
,2021, 'Long-term persistence of RBD+ memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection', Cell Reports Medicine, 2, pp. 100228, http://dx.doi.org/10.1016/j.xcrm.2021.100228
,2021, 'Acute treatment with monoclonal antibodies: Their design and their use', Microbiology Australia, 42, pp. 39 - 43, http://dx.doi.org/10.1071/MA21011
,2021, 'Altered Immune Reconstitution in Allogeneic Stem Cell Transplant Recipients with Human Immunodeficiency Virus (HIV)', Clinical Infectious Diseases, 72, pp. 1141 - 1146, http://dx.doi.org/10.1093/cid/ciaa748
,2021, 'Persistent symptoms up to four months after community and hospital- managed SARS- CoV- 2 infection', Medical Journal of Australia, http://dx.doi.org/10.5694/mja2.50963
,2021, 'The comparative ability of commonly used disease severity scores to predict death or a requirement for ICU care in patients hospitalised with possible sepsis in Yangon, Myanmar', International Journal of Infectious Diseases, 104, pp. 543 - 550, http://dx.doi.org/10.1016/j.ijid.2021.01.047
,2021, 'Sars coronavirus-2 microneutralisation and commercial serological assays correlated closely for some but not all enzyme immunoassays', Viruses, 13, http://dx.doi.org/10.3390/v13020247
,2021, 'CD73+ CD127high long-term memory CD4 T cells are highly proliferative in response to recall antigens and are early targets in hiv-1 infection', International Journal of Molecular Sciences, 22, pp. 1 - 28, http://dx.doi.org/10.3390/ijms22020912
,2021, 'Performance of a simple flow cytometric assay in diagnosing active tuberculosis', Tuberculosis, 126, http://dx.doi.org/10.1016/j.tube.2020.102017
,2021, 'Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies', Mabs, 13, http://dx.doi.org/10.1080/19420862.2021.1922134
,2021, 'Subtype-specific differences in transmission cluster dynamics of HIV-1 B and CRF01_AE in New South Wales, Australia', Journal of the International AIDS Society, 24, pp. e25655, http://dx.doi.org/10.1002/jia2.25655
,2020, 'Increased hiv subtype diversity reflecting demographic changes in the hiv epidemic in new south wales, australia', Viruses, 12, pp. 1402, http://dx.doi.org/10.3390/v12121402
,2020, 'Mucosal IL-4R antagonist HIV vaccination with SOSIP-gp140 booster can induce high-quality cytotoxic CD4+/CD8+ T cells and humoral responses in macaques', Scientific Reports, 10, http://dx.doi.org/10.1038/s41598-020-79172-7
,2020, 'Mucosal-associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy-related colitis in a pathology distinct from ulcerative colitis', Clinical and Experimental Immunology, 202, pp. 335 - 352, http://dx.doi.org/10.1111/cei.13502
,2020, 'Tfh cells in health and immunity: Potential targets for systems biology approaches to vaccination', International Journal of Molecular Sciences, 21, pp. 1 - 21, http://dx.doi.org/10.3390/ijms21228524
,2020, 'Evaluation of commercially available viral transport medium (VTM) for SARS-CoV-2 inactivation and use in point-of-care (POC) testing', Viruses, 12, pp. 1208, http://dx.doi.org/10.3390/v12111208
,